98 related articles for article (PubMed ID: 19269730)
21. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.
Carreño JE; Alvarez CE; Narciso GI; Bascarán MT; Díaz M; Bobes J
Addict Biol; 2003 Dec; 8(4):429-38. PubMed ID: 14690879
[TBL] [Abstract][Full Text] [Related]
22. Quality of life among heroin users on buprenorphine versus methadone maintenance.
Ponizovsky AM; Grinshpoon A
Am J Drug Alcohol Abuse; 2007; 33(5):631-42. PubMed ID: 17891656
[TBL] [Abstract][Full Text] [Related]
23. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.
Nielsen S; Dietze P; Lee N; Dunlop A; Taylor D
Addiction; 2007 Apr; 102(4):616-22. PubMed ID: 17286641
[TBL] [Abstract][Full Text] [Related]
24. Penile and scrotal skin necrosis after injection of crushed buprenorphine tablets.
Kluger N; Girard C; Guillot B; Bessis D
Presse Med; 2010 May; 39(5):610-1. PubMed ID: 20303699
[No Abstract] [Full Text] [Related]
25. Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status.
Kornør H; Waal H; Sandvik L
Drug Alcohol Rev; 2007 Mar; 26(2):135-41. PubMed ID: 17364848
[TBL] [Abstract][Full Text] [Related]
26. [Traumatic lesion of the glans penis. Reconstruction using a preputial flap].
Muzzonigro G; Minardi D; Caraceni E
Prog Urol; 1993 Apr; 3(2):272-5. PubMed ID: 8508211
[TBL] [Abstract][Full Text] [Related]
27. [Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)].
Duburcq A; Charpak Y; Blin P; Madec L
Rev Epidemiol Sante Publique; 2000 Aug; 48(4):363-73. PubMed ID: 11011303
[TBL] [Abstract][Full Text] [Related]
28. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.
Jones HE; Johnson RE; Jasinski DR; O'Grady KE; Chisholm CA; Choo RE; Crocetti M; Dudas R; Harrow C; Huestis MA; Jansson LM; Lantz M; Lester BM; Milio L
Drug Alcohol Depend; 2005 Jul; 79(1):1-10. PubMed ID: 15943939
[TBL] [Abstract][Full Text] [Related]
29. An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids.
Mutschler NH; Stephen BJ; Teoh SK; Mendelson JH; Mello NK
Nicotine Tob Res; 2002 May; 4(2):223-8. PubMed ID: 12028854
[TBL] [Abstract][Full Text] [Related]
30. Puffy hand syndrome due to drug addiction: a case-control study of the pathogenesis.
Andresz V; Marcantoni N; Binder F; Velten M; Alt M; Weber JC; Stephan D
Addiction; 2006 Sep; 101(9):1347-51. PubMed ID: 16911735
[TBL] [Abstract][Full Text] [Related]
31. Heroin detoxification with a single high dose of buprenorphine.
Kutz I; Reznik V
Isr J Psychiatry Relat Sci; 2002; 39(2):113-9. PubMed ID: 12227226
[TBL] [Abstract][Full Text] [Related]
32. Successful medical treatment of glans ischemia after voluntary buprenorphine injection.
Brecheteau F; Grison P; Abraham P; Lebdai S; Kemgang S; Souday V; Nedelcu C; Culty T; Larré S; Azzouzi AR; Bigot P
J Sex Med; 2013 Nov; 10(11):2866-70. PubMed ID: 23937228
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine for depression: the un-adoptable orphan.
Callaway E
Biol Psychiatry; 1996 Jun; 39(12):989-90. PubMed ID: 8780832
[No Abstract] [Full Text] [Related]
34. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
Fhima A; Henrion R; Lowenstein W; Charpak Y
Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
[TBL] [Abstract][Full Text] [Related]
35. Intravenous use of buprenorphine tablets associated with rhabdomyolysis and compressive sciatic neuropathy.
Seet RC; Lim EC
Ann Emerg Med; 2006 Apr; 47(4):396-7. PubMed ID: 16546629
[No Abstract] [Full Text] [Related]
36. Livedo-like dermatitis and necrotic lesions after high-dose buprenorphine injections: a national French survey.
Wainstein L; Bernier C; Gérardin M; Bouquié R; Espitia O; Mussini JM; Jolliet P; Victorri-Vigneau C
Br J Dermatol; 2015; 172(5):1412-4. PubMed ID: 25353069
[No Abstract] [Full Text] [Related]
37. Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone.
Soeffing JM; Rastegar DA
J Subst Abuse Treat; 2007 Dec; 33(4):401-4. PubMed ID: 17400414
[TBL] [Abstract][Full Text] [Related]
38. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
[TBL] [Abstract][Full Text] [Related]
39. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
Mammen K; Bell J
Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
[TBL] [Abstract][Full Text] [Related]
40. Complications arising from intravenous buprenorphine abuse.
Seet RC; Oh VM; Lim EC
QJM; 2007 May; 100(5):312-3. PubMed ID: 17456611
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
